Form 4: ProMIS CSO Acquires Shares, Warrants in New Offering

ProMIS Neurosciences' Chief Scientific Officer and Director, Neil Cashman, acquired 4,122 common shares and an equal number of warrants.

Summary

• Neil Cashman, Chief Scientific Officer and Director of ProMIS Neurosciences Inc. (PMN), acquired 4,122 common shares and 4,122 common share purchase warrants on February 3, 2026.
• The acquisition was made pursuant to a Securities Purchase Agreement entered into by the company with selected investors.
• The purchase price for each unit (one common share and one common share warrant) was $12.13.
• The common share warrants have an exercise price of $14.4 and are exercisable immediately.
• The warrants will expire on February 3, 2031, or earlier, within 60 days of the public announcement of topline data from cohorts treated with single ascending doses of PMN310.
• The transaction was conducted indirectly through Research Capital Corporation.
• A one-for-twenty-five reverse stock split of the company's common shares was effected on November 28, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. Insider buying, especially by a CSO, indicates confidence in the company's scientific direction and future prospects, despite the recent reverse stock split.

Positives

• A key insider, the Chief Scientific Officer and Director, is increasing their stake in the company, signaling confidence in its future prospects and scientific pipeline.
• The acquisition was part of a broader Securities Purchase Agreement, indicating successful capital raising from multiple investors.

Negatives

• The warrant exercise price ($14.4) is higher than the acquisition price ($12.13), meaning the shares need to appreciate for the warrants to be in-the-money.
• The company recently underwent a significant one-for-twenty-five reverse stock split, which often indicates a prior period of low stock performance or a need to meet listing requirements.

Risks

• The warrants' expiration is contingent on the release of topline data from the PMN310 clinical program, introducing a time-sensitive element and dependence on specific clinical trial outcomes.
• Reverse stock splits can sometimes be perceived negatively by the market, potentially impacting investor sentiment and liquidity.

Future Outlook

The future outlook is implicitly tied to the success and timely release of topline data from the PMN310 clinical program, which is a key determinant for the warrant expiration. The insider's investment suggests a positive internal view on the company's scientific progress and future prospects.

Industry Context

StockSavvy.ai notes that insider buying, particularly from a Chief Scientific Officer in a biotechnology firm, can be a strong signal of confidence in a company's pipeline and strategic direction. This is especially relevant after a reverse stock split, which often precedes efforts to stabilize the stock price and attract new investment. The focus on PMN310 highlights the company's commitment to its lead drug candidate in the neurosciences sector.

Comparison to Industry Standards

• Insider purchases by C-suite executives are generally viewed positively across industries as they align management's interests with those of shareholders, a common practice in healthy corporate governance.
• Reverse stock splits, such as the 1-for-25 split by ProMIS Neurosciences, are frequently observed in the biotechnology sector for companies whose stock prices have declined significantly, often to meet exchange listing requirements or to make the stock more appealing to institutional investors. Similar actions have been taken by companies like Aeterna Zentaris or Sorrento Therapeutics under comparable circumstances.
• The structure of acquiring both shares and warrants is a common financing mechanism in early-stage biotech, allowing investors to participate in current value while also gaining upside potential tied to future milestones.

Stakeholder Impact

• Shareholders: The insider purchase could instill confidence, but the recent reverse split might concern some. The capital raise provides funding for operations.
• Employees: Continued investment in the company's pipeline (PMN310) suggests job stability and focus on research and development.

Next Steps

• Public announcement via press release or filing of a Current Report on Form 8-K of topline data from the cohorts treated with single ascending doses of PMN310, which will trigger an earlier warrant expiration if it occurs before February 3, 2031.

Key Dates

Recommendation

While the insider purchase by the CSO is a positive signal of confidence, the recent 1-for-25 reverse stock split and the contingent nature of the warrants' expiration tied to clinical trial data introduce elements of risk and uncertainty. Investors should hold to monitor the progress of the PMN310 program and the company's overall financial stability post-reverse split before making further investment decisions.

Keywords

ProMIS Neurosciences, PMN, Neil Cashman, Insider Trading, Form 4, Common Shares, Warrants, Securities Purchase Agreement, Reverse Stock Split, Biotechnology, Neurosciences, PMN310